Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Difference between the target volume to be irradiated as measured by conventional imagining and PET
研究概览
简要总结
RATIONALE: Imaging procedures, such as PET scans, may determine the extent of cancer and help doctors plan radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy that uses a 3-dimensional image of the tumor to help focus thin beams of radiation directly on the tumor, and giving radiation therapy in higher doses over a shorter period of time, may kill more tumor cells and have fewer side effects. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This clinical trial is studying PET scans to see how well they work in patients with head and neck cancer who are undergoing 3-dimensional conformal radiation therapy and intensity-modulated radiation therapy.
详细描述
OBJECTIVES:
Primary
- To assess the value of pre-treatment PET in determining the target volume in patients with head and neck cancer undergoing three-dimensional conformational radiotherapy and intensity-modulated radiotherapy.
Secondary
- To evaluate variations in weekly fludeoxyglucose F 18 PET imaging during the first 5 weeks of treatment.
- To determine the relationship between changes in tumor metabolism during radiotherapy and control tumor at 3 months and at 1 year post-treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed head and neck cancer
- •No nasopharyngeal or paranasal sinus cancer
- •Locally advanced disease (T3 or T4)
- •Not in complete remission
- •Planning to undergo curative radiotherapy (minimum dose of 66 Gy), with or without standard treatment (i.e., platinum-based chemotherapy or biological therapy/rituximab)
- •Measurable tumor according to RECIST criteria
- •PATIENT CHARACTERISTICS:
- •WHO performance status 0-2
- •Not pregnant or nursing
- •Able to lie still for 1 hour
- •No history of progressive neoplastic disease
- •No known hypersensitivity to fludeoxyglucose F18 or any of its excipients
- •No severe or uncontrolled systemic disease, including any of the following:
- •Kidney disease
- •Liver disease
- •Cardiac disease
- •Unstable or uncompensated respiration
- •Uncontrolled diabetes (i.e., glucose ≥ 1.5 g/L)
- •No geographical, social, or psychological conditions that make follow-up impossible
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No prior surgery
- •No concurrent experimental agents
排除标准
- 未提供
结局指标
主要结局
Difference between the target volume to be irradiated as measured by conventional imagining and PET
次要结局
未报告次要终点